Nick is a Clinical Reader and consultant in Gastroenterology. His key clinical and research interests focus on intestinal inflammation in the context of inflammatory bowel diseases (such as ulcerative colitis and Crohn’s disease), but also in gut inflammation resulting from certain treatments, such as immune checkpoint inhibitors.
His research group focuses on the molecular and cellular mechanisms responsible for mediating chronic intestinal inflammation, and understanding the dialogue between intestinal microbes and host immunity. His lab is also interested in understanding how cell-specific and tissue-specific transcriptional programmes, including cytokine-responsive networks, disclose important information about disease pathogenesis, and how these "molecular signatures" can be harnessed to predict patient outcomes.
He was previously awarded a Wellcome Trust Intermediate Clinical Fellowship (2013-2019). He completed specialist registrar training in gastroenterology and internal medicine in London (Hammersmith, St Mary’s). He has also been awarded an MSc (Imperial College London) and PhD in immunology (King’s College London). Major funding has been awarded by the Wellcome Trust, MRC and Crohn’s and Colitis UK. Some key publications include; Powell N, et al. Gastroenterology (2015); 149:456-467, Goldberg R, et al. Nature Reviews in Gastroenterology and Hepatology (2015); 12:271-283, Powell N, et al. Immunity (2012); 37:674-84.
et al., 2023, Dysregulation of the environmental sensor Aryl hydrocarbon receptor affects differentiation of human colon organoids., Cell Mol Gastroenterol Hepatol
et al., 2023, Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib, Journal of Crohn's and Colitis, ISSN:1873-9946
et al., 2023, Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and dependent on IL23 and IFNg, Nature Communications, Vol:14, ISSN:2041-1723
et al., 2023, Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study, Eclinicalmedicine, Vol:64, ISSN:2589-5370
et al., 2023, TRAV26-2 T CELL RECEPTOR EXPRESSION IS ASSOCIATED WITH MUCOSAL LYMPHOCYTE RESPONSE TO WHEAT PROTEINS IN FUNCTIONAL DYSPEPSIA PATIENTS., Clin Transl Gastroenterol